UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Breast cancer research : BCR, 2017-05, Vol.19 (1), p.60-60, Article 60

2017

Volltextzugriff (PDF)

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

Cancer research (Chicago, Ill.), 2016-06, Vol.76 (11), p.3307-3318

2016

Volltextzugriff (PDF)

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER + /HER2 - Advanced Breast Cancer

Clinical cancer research, 2018-08, Vol.24 (15), p.3510-3518

2018

Volltextzugriff (PDF)

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

Molecular cancer therapeutics, 2012-08, Vol.11 (8), p.1650-1660

2012

Volltextzugriff (PDF)

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

Oncotarget, 2016-08, Vol.7 (34), p.54120-54136

2016

Volltextzugriff (PDF)

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

Molecular cancer therapeutics, 2011-05, Vol.10 (5), p.770-783

2011

Volltextzugriff (PDF)

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

Bioorganic & medicinal chemistry, 2008-12, Vol.18 (24), p.6486-6489

2008

Volltextzugriff (PDF)

Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode

Bioorganic & medicinal chemistry, 2008-08, Vol.18 (15), p.4442-4446

2008

Volltextzugriff (PDF)

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors

Bioorganic & medicinal chemistry, 2008-10, Vol.18 (20), p.5487-5492

2008

Volltextzugriff (PDF)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

British journal of cancer, 2019-02, Vol.120 (3), p.331-339

2019

Volltextzugriff (PDF)

Abstract 863: Differential activity and SERD sensitivity of clinical ESR1 mutations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.863-863

2016

Volltextzugriff (PDF)

Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A152-A152

2015

Volltextzugriff (PDF)

Abstract A146: Preclinical models relevant to the treatment of post-menopausal breast cancer

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A146-A146

2013

Volltextzugriff (PDF)

Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3650-3650

2015

Volltextzugriff (PDF)

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.DDT01-03-DDT01-03

2015

Volltextzugriff (PDF)

Abstract B127: Establishment and characterization of in vitro co-culture assays comprising tumor and fibroblast cells that more closely model the cell/stroma interactions of human tumors

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B127-B127

2011

Volltextzugriff (PDF)

Activating ESR1 mutations differentially impact the efficacy of ER antagonists

Cancer discovery, 2016-12, Vol.7 (3), p.277-287

2016

Volltextzugriff (PDF)

Structure of the HMG box motif in the B‐domain of HMG1

The EMBO journal, 1993-04, Vol.12 (4), p.1311-1319

1993

Volltextzugriff (PDF)

Analysis of the binding sites for the varicella-zoster virus gene 51 product within the viral origin of DNA replication

Virology (New York, N.Y.), 1990-08, Vol.177 (2), p.570-577

1990

Volltextzugriff (PDF)

Replication of Herpes Simplex Virus DNA: Study of an Origin Binding Protein

Weir, Hazel Margaret

1990

Volltextzugriff (PDF)

Two binding sites for the herpes simplex virus type 1 UL9 protein are required for efficient activity of the oriS replication origin

Journal of general virology, 1990-06, Vol.71 (6), p.1379-1385

1990

Volltextzugriff (PDF)

BCG vaccination: a role for vitamin D?

PloS one, 2011-01, Vol.6 (1), p.e16709-e16709

2011

Volltextzugriff (PDF)

Population Differences in Immune Responses to Bacille Calmette-Guérin Vaccination in Infancy

The Journal of infectious diseases, 2009-03, Vol.199 (6), p.795-800

2009

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(42)
Dissertationen
(1)

Sprache

Englisch
(43)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(26)
Humans
(24)
Biological And Medical Sciences
(15)
Female
(11)
Medical Sciences
(11)
Animals
(10)
Infectious Diseases
(10)
United Kingdom
(10)
Immunology
(9)
Mice
(9)
Bcg Vaccine - Immunology
(8)
Fundamental And Applied Biological Sciences. Psychology
(8)
Microbiology
(8)
Mycobacterium Tuberculosis
(7)
Oncology
(7)
Tuberculosis - Prevention & Control
(7)
Vaccination
(7)
Bcg
(6)
Malawi
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER + /HER2 - Advanced Breast Cancer

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

Optimization of a Novel Binding Motif to (E)‑3-(3,5-Difluoro-4-((1R,3R)‑2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro‑1H‑pyrido[3,4‑b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Abstract 863: Differential activity and SERD sensitivity of clinical ESR1 mutations

Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro

Abstract A146: Preclinical models relevant to the treatment of post-menopausal breast cancer

Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

Abstract B127: Establishment and characterization of in vitro co-culture assays comprising tumor and fibroblast cells that more closely model the cell/stroma interactions of human tumors

Activating ESR1 mutations differentially impact the efficacy of ER antagonists

Optimization of a Novel Binding Motif to ( E )-3-(3,5-Difluoro-4-((1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H -pyrido[3,4- b ]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Structure of the HMG box motif in the B‐domain of HMG1

Analysis of the binding sites for the varicella-zoster virus gene 51 product within the viral origin of DNA replication

Replication of Herpes Simplex Virus DNA: Study of an Origin Binding Protein

Two binding sites for the herpes simplex virus type 1 UL9 protein are required for efficient activity of the oriS replication origin

BCG vaccination: a role for vitamin D?

Population Differences in Immune Responses to Bacille Calmette-Guérin Vaccination in Infancy

Suchergebnisse filtern